加勒比人群前列腺癌根治性放疗前双参数MRI:风险分组迁移与治疗影响
本研究回顾性分析79例接受外照射放疗的加勒比男性前列腺腺癌患者,评估双参数MRI后风险分组迁移及治疗计划改变。MRI后38.0%患者风险组上调,49.4%患者治疗计划修改。结论认为高危人群放疗前应考虑前列腺MRI,因MRI分期上调可能影响治疗决策。
要点
- 双参数MRI后38.0%患者风险组上调,其中低危组85.7%、中危组50.0%、高危组16.7%发生上调。
- MRI导致49.4%患者治疗计划修改,提示放疗前MRI可影响管理决策。
- 组织学分级组(GG2 vs GG1,P=.53;GG3 vs GG1,P=.98)及既往ADT(P=.37)与风险上调无显著关联。
关键影像表现/征象
- MRI后风险组重新分类为低危1/79(1.3%)、中危19/79(24.1%)、高危51/79(64.6%)、淋巴结受累1/79(1.3%)、转移性疾病7/79(8.9%)。
- MRI前风险分层为低危7/79(8.9%)、中危36/79(45.6%)、高危36/79(45.6%)。
- MRI后30/79(38.0%)患者风险组上调;原低危组6/7(85.7%)、中危组18/36(50.0%)、高危组6/36(16.7%)发生上调。
诊断标准与关键数值
- 风险分层依据NCCN风险类别,使用血清PSA、直肠指检、活检组织学分级组、既往ADT及既往CT结果。
- 风险组上调与组织学分级组无显著关联:GG2 vs GG1,P=.53;GG3 vs GG1,P=.98。
- 风险组上调与既往ADT无显著关联(P=.37)。
临床应用与阅片要点
- 对接受外照射放疗的前列腺癌患者,尤其是高危人群,可考虑放疗前前列腺MRI以评估风险组迁移。
- MRI后风险组上调可能影响治疗计划修改,本研究中49.4%患者治疗计划发生改变。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess risk-group migration and subsequent management change following biparametric MRI using a risk-stratified approach in a group of Caribbean men with prostate adenocarcinoma being offered external beam radiation therapy (EBRT).
MATERIALS AND METHODS: This retrospective study assessed the biparametric MRI findings in men who opted for EBRT from January 2018 to June 2019 (n = 79; mean age, 67.9 years ± 6.2 [standard deviation]). Serum prostate-specific antigen level, digital rectal examination findings, histologic grade group (GG) from transrectal US-guided biopsy, prior androgen deprivation therapy (ADT), and any prior CT results were used to stratify patients into low-, intermediate-, and high-risk groups, according to the National Comprehensive Cancer Network risk categories. Risk-group stratification prior to MRI separated patients into low- (seven of 79 [8.9%]), intermediate- (36 of 79 [45.6%]) and high-risk (36 of 79 [45.6%]) groups. Following MRI, any risk group (low, intermediate, high, nodal involvement, and metastatic disease) or oncologic management changes were recorded. Multivariable binary logistic regression analyses were used to assess predictor of upgrade status, with adjustment for demographic covariates jointly.
RESULTS: Following MRI, 30 of 79 (38.0%) patients had risk-group upshifts compared with their original assessment. Patients were recategorized into low risk (one of 79, 1.3%), intermediate risk (19 of 79, 24.1%), high risk (51 of 79, 64.6%), nodal involvement (one of 79, 1.3%), and metastatic disease (seven of 79, 8.9%). From the original groupings, there were six of seven (85.7%) from the low group, 18 of 36 (50.0%) from the intermediate group, and six of 36 (16.7%) from the high group that had risk group upward shifts. There was no association with GG: GG2 versus GG1, P = .53; GG3 versus GG1, P = .98; or prior ADT (P = .37) and the adjusted odds of risk-group upshifts. MRI findings resulted in treatment plan modification for 39 of 79 (49.4%) men overall.
CONCLUSION: Prostate MRI should be considered for patients in high-risk populations prior to EBRT because upstaging from MR image assessment may have implications for modification of treatment.Keywords: MR-Imaging, Prostate, Radiation Therapy© RSNA, 2020See the commentary by Davenport and Shankar in this issue.
引用
- Gosein MA, Narinesingh D, Motilal S, et al. Biparametric MRI prior to Radical Radiation Therapy for Prostate Cancer in a Caribbean Population: Implications for Risk Group Stratification and Treatment. Radiol Imaging Cancer. 2020. PMID: 33778724. doi:10.1148/rycan.2020200007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。